Report #2829262

Received Mar 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 60 yrs
State: WA
Recovered: Not recovered
Vaccinated: Feb 3, 2025
Onset: Feb 3, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
PNC21	PNEUMO (CAPVAXIVE)	MERCK & CO. INC.	UNK	Y011819	OT

Symptoms (1)

Rash

Symptom narrative

rash; Information has been received from Business Partner/CRO on 12-Feb-2025. This spontaneous report was received from a/an Pharmacist and refers to a(n) 60-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 03-Feb-2025, the patient started therapy with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE), Solution for injection (lot #Y011819, expiration date: 01-Oct-2025) 0.5 mL (0.5ml/dose), administered by Intramuscular route. On an unknown date, the patient started therapy with . The patient started therapy with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE), for the treatment of Age over 50 years old. On 03-Feb-2025, the patient experienced rash. At the reporting time, the patient was recovering from rash. The action taken with Pneumococcal 21-valent Conjugate Vaccine was reported as not applicable. The causal relationship between the event of rash and Pneumococcal 21-valent Conjugate Vaccine was unknown/not reported/not provided.